title: Retroperitoneal soft tissue sarcoma.
abstract: The objective of the current study was to define the optimal treatment for patients with retroperitoneal soft tissue sarcomas (RPS). The authors conducted a review of the pertinent literature and found that the majority of patients had locally advanced RPS at the time of diagnosis. Surgery was the mainstay of treatment, and macroscopic total excision was feasible in approximately 50-67% of patients. The 5-year probability of local control was approximately 50%, and the likelihood of developing distant metastasis was approximately 20-30%. The 5-year survival rate was approximately 50%, and deaths due to recurrent RPS continued to occur after 5 years. Postoperative radiotherapy (RT) decreased the likelihood of local recurrence, although it demonstrated no impact on survival. Adjuvant chemotherapy had no proven efficacy. The factor that was found to have the greatest impact on the prognosis for patients with RPS was the ability to achieve a macroscopic total resection. The authors concluded that RPS usually is advanced at the time of diagnosis. The optimal treatment was complete resection. Most patients experienced recurrent disease after surgery, and the most common site of failure was local. Adjuvant RT reduced the risk of local recurrence, but its impact on survival was questionable.
authors: Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USA. mendewil@shands.ufl.edu
authors: William M
authors: WM
authors: Mendenhall
authors: Robert A
authors: RA
authors: Zlotecki
authors: Steven N
authors: SN
authors: Hochwald
authors: Alan W
authors: AW
authors: Hemming
authors: Stephen R
authors: SR
authors: Grobmyer
authors: William G
authors: WG
authors: Cance
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D013505:Digestive System Surgical Procedures; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D012186:Retroperitoneal Neoplasms / Q000628:therapy*; D012509:Sarcoma / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000628:therapy*; D016896:Treatment Outcome